DYNAVAX TECHNOLOGI revenue breakdown overview

DYNAVAX TECHNOLOGI revenue for the last year amounted to 195.57 M CHF, the most of which — 195.57 M CHF — came from its highest performing source at the moment, Innovative Vaccines, the year earlier bringing 668.28 M CHF. The greatest contribution to the revenue figure was made by United States — last year it brought DYNAVAX TECHNOLOGI 194.44 M CHF, and the year before that — 123.70 M CHF.